Journal article
Acute decrease in HIV-1 viral load after initiation of zidovudine therapy: implications for interrupting vertical transmission
Pediatric AIDS and HIV infection, Vol.6(6), pp.358-361
12/1995
PMID: 11361462
Abstract
Use of zidovudine (AZT) in pregnant women has recently been reported to reduce the rate of vertical transmission of human immunodeficiency virus type 1 (HIV-1) possibly through a reduction in maternal viral load. To determine how quickly AZT is able to reduce viral load, infectious virus and plasma HIV-1 RNA were sequentially measured in an HIV-1-infected patient at short intervals (hours) after initiation of oral AZT. Peripheral blood samples were collected at baseline, 1, 2, 4, 8, 12, 24, 48 hours, and 1 week after initiation of AZT therapy (500 mg/day) for quantitative plasma HIV-1 RNA levels, p24 antigen levels, and AZT levels. Quantitative HIV-1 peripheral blood mononuclear cell and plasma cultures, CD4 cell counts, and MT-2 cell assays for syncytium-inducing phenotype were performed at baseline, 1, 2 days, and 1 week after initiation of AZT therapy. A significant drop in viral load did not occur until after 24-48 hours. AZT should probably be administered at least 2 days prior to anticipated delivery, if a reduced maternal viral load is responsible for AZT's efficacy in preventing vertical transmission.
Details
- Title: Subtitle
- Acute decrease in HIV-1 viral load after initiation of zidovudine therapy: implications for interrupting vertical transmission
- Creators
- J B Jackson - Institute of Pathology and Department of Geographic Medicine, Case Western Reserve University, University Hospitals of Cleveland, OH, USA
- Resource Type
- Journal article
- Publication Details
- Pediatric AIDS and HIV infection, Vol.6(6), pp.358-361
- Publisher
- United States
- PMID
- 11361462
- ISSN
- 1045-5418
- Language
- English
- Date published
- 12/1995
- Academic Unit
- Pathology; VPMA - Administration
- Record Identifier
- 9984046904902771
Metrics
28 Record Views